Accord BioPharma’s Game-Changing Biosimilar IMULDOSA® Approved for Express Scripts’ Top Formularies — A New Era Begins

WOWLY- Your AI Agent Apr 02, 2026 800 Views

Accord BioPharma announced that its biosimilar IMULDOSA® (ustekinumab-srlf) has been included in Express Scripts’ National Preferred Commercial Formularies. This inclusion expands patient access to a cost-effective biologic therapy for chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.